Skip to main content
    D

    Dr. Reddy’s Laboratories Ltd ADR (RDY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $14.70
    -0.04 (-0.27%)

    Market Cap: $12.29B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Dr. Reddy’s Laboratories Ltd ADR (RDY) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Dr. Reddy’s Laboratories Ltd ADR (RDY) trades at 39.6x trailing earnings and 3.5x sales. Its P/S of 3.5x is below its 5-year median of 4.8x. Its forward P/E is 31.6x. The median P/E across 9 similar companies is 18.4x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 25.3% higher over the next year. Its free cash flow yield is 1.1%.

    MultipleValue
    P/E (trailing)39.6x
    Forward P/E31.6x
    Price to sales3.5x
    Price to book3.0x
    EV/EBITDA22.2x
    Price to FCF94.2x
    EV/FCF98.9x
    PEG2.0
    FCF yield1.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 11.8% below 3.4x.

    MultipleCurrent5-year median10-year median
    P/S3.5x4.8xN/A
    P/B3.0x3.5x3.4x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 99 months (10-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 2.6x in 2020 to 7.8x in 2021.

    Year endPriceP/SP/B
    2025$14.043.0x2.8x
    2024$15.793.6x3.5x
    2023$13.926.8x3.6x
    2022$10.355.7x3.2x
    2021$13.087.8x316.9x
    2020$14.262.6x1.0x
    2019$8.122.8x3.2x
    2018$7.54N/AN/A
    2017$7.51N/A0.6x
    2016$9.06N/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    P/E history is shown only for companies that report in US dollars.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RDY

    What is RDY's forward P/E ratio?

    Dr. Reddy’s Laboratories Ltd ADR has a forward P/E ratio of 31.6x.

    Is RDY stock overvalued?

    GNG's valuation label for RDY is Overvalued. Its P/E of 39.6x compares with a median of 18.4x across 9 similar companies.

    What is RDY's price to sales ratio?

    Dr. Reddy’s Laboratories Ltd ADR has a price to sales ratio of 3.5x.

    What is RDY's PEG ratio?

    Dr. Reddy’s Laboratories Ltd ADR has a PEG ratio of 2.0.